Important Safety Information ⬇

  • A severe allergic reaction (e.g. anaphylaxis, for example) to any ingredient that is part of the Prevnar 20(tm) Prevnar 20(tm), Prevnar 13(r) or diphtheria toxoid , is a warning sign.
  • Data on the safety and immunogenicity of Prevnar 20(tm) are not available for those who are who are immunocompromised and vaccines is recommended in a case-by-case basis. Based on experiences with pneumococcal vaccinations, those who have a compromised immune system may experience diminished immunity against Prevnar 20(tm)
  • Patients with a compromised immune system or who have impaired immune response because of the use of immunosuppressive therapy could have a reduced antibodies towards Prevnar 13(r)
  • In the case of Prevnar 20(tm) in adult patients aged 18 or older the most frequently adverse reactions (>10 percent) included discomfort around the injection area and muscle pain, fatigue arthritis, and headache. In addition, swelling of the injection site was also observed (>10 percent) for those aged 18 to 60 years old.
  • In the case of Prevnar 13(r), adults aged 18 or older The most frequently adverse reactions (>5 percent) were redness, pain and swelling around an injection point, as well as limitation of arm motion and fatigue, headache and muscle pain joint pain, decreased appetite vomiting as well as chills, fever and the appearance of a rash.